By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – CVS Caremark and Generation Health today announced the 13 drug therapies that will be included in the initial offering of their integrated Genetic Benefit Management service.

The firms said that they are offering the industry's first Best Test Genetics Network, which coordinates pharmacogenomic testing for members of CVS Caremark's network.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.